Intelligent Bio Solutions Inc. announced preliminary, unaudited revenue results for the fiscal fourth quarter and full-year ended June 30, 2025. The company anticipates fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year-over-year.
This growth reflects continued demand for its higher-margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters, demonstrating consistent operational momentum.
President and CEO Harry Simeonidis stated that fiscal 2025 represented a year of disciplined execution and strategic investment. The company also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling global operations through system upgrades and localization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.